Welcome to our dedicated page for Glycomimetics SEC filings (Ticker: GLYC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The GLYC SEC filings page on Stock Titan offers access to regulatory documents associated with GlycoMimetics, Inc. before and through its business combination with Crescent Biopharma, Inc. GlycoMimetics described itself as a late clinical-stage biotechnology company focused on glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and inflammatory diseases. Its filings provide formal detail on this research focus, its investigational candidates, and the corporate transactions that culminated in the transition to Crescent Biopharma, Inc.
Key filings include current reports on Form 8-K that describe material events. For example, a June 18, 2025 Form 8-K explains that on June 13, 2025, GlycoMimetics consummated a business combination with Crescent Biopharma, Inc., and that after the merger the company changed its name to Crescent Biopharma, Inc. and its ordinary shares trade on The Nasdaq Capital Market under the symbol CBIO. This filing also outlines how GlycoMimetics and Crescent securities were converted in the merger and summarizes ownership percentages of the post-merger company.
Another Form 8-K dated July 31, 2025, filed under the Crescent Biopharma, Inc. name, describes the adoption of an executive severance plan for employees at the vice president level and above. Such filings provide insight into governance, compensation arrangements, and the structure of executive protections in connection with corporate change-of-control events.
On Stock Titan, users can review these and other GLYC-related filings with the support of AI-powered summaries that highlight key terms, transaction structures, and governance provisions. Real-time updates from EDGAR ensure that newly filed 8-Ks and other forms associated with the historical GLYC registration are captured. For investors and researchers examining the legacy GlycoMimetics entity and its merger into Crescent Biopharma, this page serves as a focused entry point into the company’s regulatory history and the documentation of its transition to trading under CBIO.
Form 4 filing for GlycoMimetics, Inc. (GLYC) discloses that Fairmount Funds Management LLC, together with affiliated entities (Fairmount Healthcare Fund II L.P., Tomas Kiselak and Peter Harwin), received a grant of 9,023 stock options on 23 Jun 2025. The option has an exercise price of $15.30 and vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, contingent on continued service.
The options are held indirectly by Mr. Harwin for the benefit of investment vehicles managed by Fairmount, which collectively qualify as 10% owners and directors by deputization. Following the grant, the reporting persons own 9,023 derivative securities (no change to non-derivative common share holdings is reported).
No purchase or sale of already-outstanding common shares occurred; the filing represents a routine director compensation award. The size of the grant is immaterial relative to GlycoMimetics’ public float and does not meaningfully affect ownership concentration or potential dilution.
Form 4 highlights: On 06/23/2025, director Alexandra Balcom received a stock option for 9,023 ordinary shares of GlycoMimetics Inc. (ticker indicated as CBIO) at an exercise price of $15.30 per share. The option vests in full on the earlier of 23 Jun 2026 or the company’s next annual shareholder meeting, subject to her continued board service, and expires on 23 Jun 2035.
No other equity transactions—purchases, sales, or additional share ownership—were disclosed. After the grant, Ms. Balcom beneficially owns 9,023 derivative securities directly; Table I for non-derivative holdings is blank, suggesting she held no common shares before the grant.
Implications for investors: The award is part of routine director compensation and does not represent an open-market purchase; therefore, it does not immediately affect the share count or cash flow. The filing adds a modest potential dilution—approximately 9 k shares—once the option is exercised. While small relative to total shares outstanding, the grant aligns the director’s long-term incentives with shareholder value appreciation.
On June 23, 2025, GlycoMimetics, Inc. (GLYC) director David Charles Lubner filed a Form 4 reporting the grant of 9,023 non-qualified stock options at an exercise price of $15.30 per share. The options were acquired for $0.00 and will vest in full on the earlier of June 23, 2026 or the company’s next annual shareholder meeting, subject to continued board service. They carry a 10-year term, expiring June 23, 2035, and are held directly by the director. No open-market purchases, sales, or dispositions of common shares were reported. The filing represents a routine equity-compensation award and does not convey new information about GlycoMimetics’ operating performance, strategy, or near-term cash flows.
Form 3 overview: On June 23, 2025, officer Ryan Lynch filed an initial statement of beneficial ownership after a multi-step transaction in which GlycoMimetics, Inc. merged with Crescent Biopharma, Inc., adopted the Crescent Biopharma, Inc. name and, on June 16, 2025, redomiciled from Delaware to the Cayman Islands. The filing establishes Lynch’s baseline insider position in the newly constituted issuer (ticker: CBIO).
Equity award details: Lynch, who serves as Treasurer, Senior Vice President of Finance and Chief Accounting Officer, reports a stock option for 105,706 ordinary shares at an exercise price of $6.16. The award originated from his pre-merger Crescent option and now entitles him to acquire an identical number of Cayman ordinary shares. Vesting is 25 % on December 27 2025, with the balance vesting in equal monthly instalments through December 27 2028, contingent upon continued service.
Ownership structure and timing: All derivative securities are held directly; no non-derivative share ownership is reported. The Form 3 provides the first Section 16 disclosure for Lynch following the June 13 2025 closing of the merger, allowing investors to track future changes to his stake.
Form 3 highlights a new insider position created by the completion of a complex reverse-merger and redomiciliation involving GlycoMimetics, Inc. (now Crescent Biopharma, Inc.; ticker remains CBIO in the filing header, GLYC in metadata). Richard William Scalzo, recently appointed Chief Financial Officer, has filed his initial statement of beneficial ownership dated 23 June 2025 for an event that occurred on 13 June 2025.
Corporate restructuring. • On 13 June 2025 a two-step merger converted Crescent Biopharma into a wholly owned subsidiary of GlycoMimetics, after which the parent renamed itself Crescent Biopharma, Inc. • On 16 June 2025 the issuer completed a change of domicile from Delaware to the Cayman Islands. All existing equity awards automatically converted into rights over Cayman ordinary shares on a one-for-one basis and under identical terms.
Insider equity. Scalzo reports no non-derivative common shares but holds a single derivative position:
- Stock options: 234,383 ordinary shares, exercise price $9.56.
- Vesting schedule: 25 % on 1 Apr 2026; balance vests monthly until 1 Apr 2029, contingent on continued service.
- Expiration: 1 Apr 2035.
Investor take-away. The filing formally registers the CFO as an insider and discloses his incentive package following the merger and offshore reorganisation. Although no immediate share purchases are shown, the sizable option grant aligns compensation with long-term share performance and signals management continuity post-transaction.